Supportive Management of Disseminated Intravascular Coagulation (DIC)

Transfusion Support

In actively bleeding DIC, maintain platelet counts above 50 × 10⁹/L by transfusing platelets; lower thresholds ( < 30 × 10⁹/L for acute promyelocytic leukemia, < 20 × 10⁹/L for other malignancies) are used for high‑risk patients without active hemorrhage. 1
Fresh‑frozen plasma should be given at 15–30 mL/kg to bleeding DIC patients, with dose adjustments guided by clinical response rather than isolated PT/aPTT prolongation. 1
When volume overload is a concern, prothrombin complex concentrates may replace plasma, recognizing they provide only selected clotting factors. 1
Persistent hypofibrinogenemia (fibrinogen < 1.5 g/L) despite plasma support warrants administration of two pools of cryoprecipitate or fibrinogen concentrate. 1
Transfused platelets and clotting factors often have a short lifespan in DIC due to ongoing activation and consumption, frequently necessitating repeated dosing. 1

Anticoagulant Therapy (Selected Cases)

Heparin anticoagulation is indicated for thrombosis‑predominant DIC, such as arterial/venous thromboembolism, severe purpura fulminans, or vascular skin infarction. 1
In solid‑tumor‑associated DIC, prophylactic heparin may be considered when there are no contraindications (e.g., platelet count ≥ 20 × 10⁹/L and no active bleeding). 1
For patients at high bleeding risk with renal impairment, unfractionated heparin is preferred because of its rapid reversibility; otherwise, low‑molecular‑weight heparin is recommended. 1
Abnormal coagulation screens alone should not preclude anticoagulation in the absence of bleeding, as DIC reflects a rebalanced hemostatic state with simultaneous loss of pro‑ and anti‑coagulant factors. 1
Heparin must be avoided in hyperfibrinolytic DIC, where it can exacerbate bleeding. 1

Treatments Without a Role in DIC

Corticosteroids have no established benefit and are not recommended by major DIC guidelines. 1
Antiplatelet agents are not indicated and may increase bleeding risk. 1

Clinical Management Algorithm

Treat the underlying trigger of DIC as the primary therapeutic goal. 1
Identify the clinical phenotype (bleeding‑predominant vs. thrombosis‑predominant) to guide therapy.
For a bleeding phenotype, provide aggressive transfusion support: platelets to >50 × 10⁹/L, plasma 15–30 mL/kg, and fibrinogen replacement if <1.5 g/L. 1
For a thrombotic phenotype, initiate therapeutic heparin anticoagulation despite abnormal coagulation tests. 1
Dynamic monitoring of platelets, coagulation parameters, fibrinogen, and D‑dimer is essential, with frequency adjusted to clinical severity.

Common Pitfalls

Do not transfuse solely based on laboratory abnormalities; clinical bleeding or procedural risk must drive transfusion decisions. 1
Do not withhold anticoagulation solely because of prolonged PT/aPTT in thrombotic DIC. 1
Routine use of antifibrinolytics (e.g., tranexamic acid) is discouraged; they should be reserved for refractory bleeding with documented hyperfibrinolysis. 1
Recognize that transfused blood products have reduced survival in active DIC, often requiring repeated administrations. 1

Manejo de la Coagulación Intravascular Diseminada (CID)

Principios generales del tratamiento

El tratamiento fundamental de la CID es abordar la causa subyacente, complementado con medidas de soporte que incluyen transfusiones de productos sanguíneos según umbrales específicos y, en casos seleccionados, anticoagulación con heparina 2, 3, 4
El reconocimiento temprano y el diagnóstico oportuno son cruciales para mejorar el pronóstico 3, 4
El tratamiento de la enfermedad subyacente es la piedra angular del manejo de la CID 2, 3, 4

Monitorización

Se recomienda monitorización regular del hemograma completo y pruebas de coagulación, incluyendo fibrinógeno y dímero D 5, 6
La frecuencia de monitorización puede variar desde diaria hasta mensual según el caso clínico 7, 5
Una disminución del 30% o más en el recuento plaquetario puede ser diagnóstica de CID subclínica 7, 5

Medidas de soporte hemostático

En pacientes con CID y sangrado activo: mantener plaquetas >50×10⁹/L 2, 8, 3
En pacientes con alto riesgo de sangrado sin hemorragia activa: transfundir si plaquetas <30×10⁹/L en leucemia promielocítica aguda (LPA) o <20×10⁹/L en otros tipos de cáncer 8, 3, 4
La vida media de las plaquetas transfundidas puede ser muy corta en CID con activación vigorosa de la coagulación 8, 9
En pacientes con CID y sangrado activo: administrar 15-30 mL/kg de plasma fresco congelado (PFC) 3, 4
En casos de sangrado activo con valores persistentemente bajos de fibrinógeno (<1,5 g/L): administrar dos unidades de crioprecipitado o concentrado de fibrinógeno 3, 4

Anticoagulación

La heparina está indicada principalmente en formas de CID con predominio trombótico 2, 3, 10
En CID asociada a tumores sólidos: considerar profilaxis con heparina en ausencia de contraindicaciones (plaquetas <20×10⁹/L o sangrado activo) 10, 11
En pacientes con alto riesgo de sangrado y falla renal: preferir heparina no fraccionada (HNF) por su reversibilidad 11, 9
En otros casos: preferir heparina de bajo peso molecular (HBPM) 11, 9
Evitar heparina en CID con hiperfibrinólisis predominante [10, @17@]

Consideraciones especiales

El tratamiento de la neoplasia subyacente es fundamental en CID en cáncer 3, 4
En LPA, el inicio temprano de la terapia de inducción logra buena resolución de la CID 2, 3
En tumores sólidos con eventos tromboembólicos: HBPM a dosis terapéutica durante 6 meses (primer mes a dosis completa, 5 meses al 75% de la dosis) ha demostrado ser superior a warfarina 10, 11

Advertencias y precauciones

Las anormalidades en las pruebas de coagulación por sí solas no deben considerarse una contraindicación absoluta para la anticoagulación en ausencia de sangrado 11, 9
La vida media de los productos transfundidos puede ser muy corta en CID con activación intensa de la coagulación 8, 9

Transfusion Recommendations for Disseminated Intravascular Coagulation (DIC)

General Guideline Principles

In patients who have laboratory evidence of DIC but no active bleeding, cryoprecipitate should not be administered; transfusion therapy is reserved for those with bleeding, not for isolated abnormal test results. Strong guideline recommendation. 12, 13
The 2025 Association of Anaesthetists guideline states that fresh frozen plasma (and, by extension, cryoprecipitate) is indicated only for DIC when there is active bleeding or the patient is at high risk of bleeding (e.g., planned surgery or invasive procedure). Strong recommendation. 13

Indications for Cryoprecipitate in DIC

The 2016 AAGBI guideline lists a fibrinogen threshold of < 1.0 g/L as an indication for cryoprecipitate in DIC, but emphasizes that this applies only when the patient is actively bleeding. Conditional recommendation. 14, 15

Prophylactic Use Prior to Procedures

The 2025 guidelines report no good evidence supporting prophylactic use of fresh frozen plasma (or cryoprecipitate) to correct abnormal coagulation tests before low‑risk invasive procedures in critically ill patients; such prophylaxis is not recommended. Strong recommendation. 12, 13
When an invasive procedure is planned that places the patient at high risk of bleeding, prophylactic correction of coagulation abnormalities—including fibrinogen replacement—may be appropriate according to the 2025 guideline. Conditional recommendation. 13

Interpretation of Coagulation Tests

In critically ill patients, abnormal PT or aPTT values are poor predictors of bleeding and do not reliably reflect true hemostatic status; therefore, these laboratory abnormalities should not drive transfusion decisions in DIC. Strong recommendation. 12, 13

Platelet Transfusion Guidelines in Disseminated Intravascular Coagulation (DIC)

Transfusion Thresholds for Invasive Procedures

The American Association of Blood Banks (AABB) 2015 guidelines recommend transfusing platelets to keep the count above 50 × 10⁹/L before major invasive procedures in patients with DIC. 16

General Platelet Transfusion Thresholds in Thrombocytopenia (non‑DIC context)

The AABB 2015 guidelines set a prophylactic platelet transfusion threshold of 10 × 10⁹/L for hypoproliferative thrombocytopenia; these thresholds do not apply to DIC, where platelet consumption rather than under‑production drives thrombocytopenia and transfusion decisions should be based on active bleeding or procedural risk. [16][17][18][19]

Management of Disseminated Intravascular Coagulation (DIC)

1. Treat the Underlying Trigger

Aggressive identification and treatment of the precipitating condition (e.g., sepsis, malignancy, trauma, obstetric complications) is the primary therapeutic goal; DIC will not resolve without addressing the root cause. 20, 21
In malignancy‑associated DIC, early initiation of chemotherapy—especially in acute promyelocytic leukemia—produces rapid DIC resolution. 20, 22

2. Anticoagulation Strategies

2.1 Thrombosis‑Predominant DIC

Therapeutic‑dose heparin (preferably low‑molecular‑weight heparin) should be started for arterial/venous thromboembolism, severe purpura fulminans, or vascular skin infarction, provided there is no active bleeding. 20, 21, 22
In cancer‑associated DIC without active bleeding, prophylactic anticoagulation is advisable unless platelets are <20 × 10⁹/L or bleeding is present. 20, 21, 22

2.2 Bleeding‑Predominant DIC

Anticoagulation should not be withheld solely because PT/aPTT are prolonged; the hemostatic balance in DIC permits anticoagulation when bleeding is absent. 20

2.3 Hyperfibrinolytic DIC

Heparin should be avoided because it can worsen bleeding in this phenotype. 20

3. Use of Antifibrinolytics

Routine administration of tranexamic acid is not recommended in DIC and may increase thrombotic events. 20, 22, 23
Tranexamic acid may be considered only for therapy‑resistant bleeding that is documented to be due to hyperfibrinolysis. 20, 22

4. Agents to Avoid

Recombinant Factor VIIa is not recommended because its benefit is uncertain and it carries a definite thrombotic risk. 20, 22, 23

5. Monitoring and Laboratory Assessment

Serial laboratory testing—including complete blood count, PT/aPTT, fibrinogen, and D‑dimer—is essential for tracking DIC activity. Frequency should be adjusted to clinical severity (e.g., daily in acute phases). 20, 21, 23
Ongoing assessment for organ dysfunction and verification that the underlying trigger is being adequately treated are critical components of management. 20, 21, 23

6. Special Clinical Scenarios

In patients who develop a new thrombus while having severe thrombocytopenia (platelet count <25–50 × 10⁹/L), management options include:

Phenotype Classification and Clinical Presentation of Disseminated Intravascular Coagulation

Clinical Phenotypes

Three distinct DIC phenotypes (procoagulant, hyperfibrinolytic, and subclinical) guide therapeutic strategy – the phenotype determines whether anticoagulation or transfusion support is prioritized. 24, 25

Procoagulant (Thrombosis‑Predominant) DIC

Associated malignancies: most frequently observed in patients with pancreatic cancer and other adenocarcinomas. 24, 25
Typical clinical manifestations: arterial ischemia (e.g., patchy skin discoloration, digital ischemia, stroke), venous thromboembolism, and microvascular thrombosis. 24, 25

Hyperfibrinolytic (Bleeding‑Predominant) DIC

Associated conditions: commonly occurs in acute promyelocytic leukemia and metastatic prostate cancer. 24, 25
Typical clinical manifestations: widespread bruising, mucosal bleeding, central‑nervous‑system hemorrhage, and gastrointestinal bleeding. 24, 25

Subclinical DIC

Laboratory profile without overt clinical signs: isolated thrombocytopenia, low fibrinogen levels, and elevated D‑dimer, but no visible bleeding or thrombosis. 24, 25
Risk of progression: may evolve into overt DIC if the underlying disease remains untreated. (derived from the same source) 24, 25